Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2009.0105


Bevacizumab: Limitations for Breast Cancer Treatment


Since there is no abstract available we provide the first paragraph

One protein with a central role in promoting angiogenesis is vascular endothelial growth factor (VEGF). By inhibiting this protein with anti-VEGF agents, it may limit a tumour’s blood supply and prevent its growth. It sounds a logical anticancer concept. Currently, following Food and Drug Administration (FDA) approval, oncologists widely use bevacizumab in the clinic for the metastatic solid tumors including breast cancer.

But what’s about bevacizumab resistance? Intrinsic or acquired resistance is often and represents a plausible explanation for the treatment failure with molecularly targeting agents [1]. Thus, the modest efficacy of bevacizumab could be somewhat unsurprising. But potential reduced overall survival for some patients requires consideration and further evaluation. Indeed, after initial enthusiasm, more current data suggest caution.
You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004